AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28741683 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 40
Study 25042729 — intervention group
Group type: COMPARATOR
Intervention: Grid laser photocoagulation
Number of subjects: 30
Study 25042729 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal ranibizumab (IVR) 0.5 mg
Number of subjects: 30
Study 25042729 — intervention group
Group type: COMPARATOR
Intervention: Combination of grid laser and IVR
Number of subjects: 30
Study 23414646 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Intervention Program (CIP) for 6 months, 2 hours per session, twice per week.
Number of subjects: 46
Study 23414646 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 46
Study 21195572 — intervention group
Group type: EXPERIMENTAL
Intervention: 550 mg iodine/(kg of LBW)
Number of subjects: 136
Study 21195572 — intervention group
Group type: EXPERIMENTAL
Intervention: 650 mg iodine/(kg of LBW)
Number of subjects: 136
Study 21195572 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg iodine/(kg of LBW)
Number of subjects: 136
Study 21195572 — intervention group
Group type: COMPARATOR
Intervention: 600 mg iodine/(kg of TBW)
Number of subjects: 136
Study 19418859 — intervention group
Group type: EXPERIMENTAL
Intervention: Magic FoamCord (MFC) system
Number of subjects: 269
Study 19418859 — intervention group
Group type: COMPARATOR
Intervention: Single cord retraction technique
Number of subjects: 269
Study 17565936 — intervention group
Group type: EXPERIMENTAL
Intervention: Black cohosh
Number of subjects: 120
Study 17565936 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 120
Study 17565936 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 120
Study 15087991 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 0
Study 11843764 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (IVIG) treatment
Number of subjects: 12
Study 11843764 — intervention group
Group type: COMPARATOR
Intervention: Plasma exchange
Number of subjects: 12
Study 11843764 — intervention group
Group type: COMPARATOR
Intervention: Comparison between IVIG and Plasma exchange
Number of subjects: 12
Study 9738724 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day pulse course of dexamethasone
Number of subjects: 40
Study 9738724 — intervention group
Group type: COMPARATOR
Intervention: 42-day course of dexamethasone
Number of subjects: 40
Study 8113278 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthosis
Number of subjects: 122
Study 8113278 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 122
Study 3177859 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure
Number of subjects: 40
Study 3177859 — intervention group
Group type: COMPARATOR
Intervention: Stimulation of cricoid pressure
Number of subjects: 40
Study 30257661 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding education and support intervention (BFESI)
Number of subjects: 432
Study 30257661 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 432
Study 27722974 — intervention group
Group type: EXPERIMENTAL
Intervention: COMMODITY12 mHealth system
Number of subjects: 60
Study 23761871 — intervention group
Group type: EXPERIMENTAL
Intervention: micronized diosmin + hesperidin
Number of subjects: 136
Study 23761871 — intervention group
Group type: EXPERIMENTAL
Intervention: aminaphthone
Number of subjects: 136
Study 23761871 — intervention group
Group type: EXPERIMENTAL
Intervention: coumarin + troxerutin
Number of subjects: 136
Study 23761871 — intervention group
Group type: COMPARATOR
Intervention: placebo (starch)
Number of subjects: 136
Study 23084280 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated multi-component CVD risk reduction intervention
Number of subjects: 1146
Study 23084280 — intervention group
Group type: COMPARATOR
Intervention: Usual care by physicians
Number of subjects: 1146
Study 20157663 — intervention group
Group type: EXPERIMENTAL
Intervention: Quixfil (Xeno III)
Number of subjects: 43
Study 20157663 — intervention group
Group type: COMPARATOR
Intervention: Tetric Ceram (Syntac Classic)
Number of subjects: 43
Study 17991697 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume sprint interval training (SIT) - 4 to 6 repeats of a 30 s 'all out' Wingate Test, 3 days per week, mean power output approximately 500 W.
Number of subjects: 20
Study 17991697 — intervention group
Group type: COMPARATOR
Intervention: Traditional endurance training (ET) - 40-60 min of continuous cycling at approximately 65% workload, 5 days per week, mean power output approximately 150 W.
Number of subjects: 20
Study 16042771 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-naïve asthmatic children
Number of subjects: 36
Study 16042771 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled steroid-treated asthmatic children
Number of subjects: 36
Study 16042771 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-treated asthmatic children
Number of subjects: 36
Study 12125393 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrodermal stimulation prior to presentation of word list
Number of subjects: 0
Study 12125393 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrodermal stimulation applied before word presentation in women
Number of subjects: 0
Study 12125393 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrodermal stimulation applied after word presentation in men
Number of subjects: 0
Study 10499179 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8694167 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 40
Study 8694167 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol + Ephedrine 15 mg
Number of subjects: 40
Study 8694167 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol + Ephedrine 20 mg
Number of subjects: 40
Study 8694167 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol + Ephedrine 10 mg
Number of subjects: 40
Study 8694167 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 40
Study 2004573 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodyne‐Lubricant Jelly (ALJ) containing Dicaini, Lidocaine
Number of subjects: 372
Study 2004573 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 372
Study 2004573 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodyne‐Lubricant Jelly (ALJ) applied intracervically
Number of subjects: 372
Study 2004573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 6507998 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methylprednisolone (32 mg)
Number of subjects: 12
Study 6507998 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (128 mg)
Number of subjects: 12
Study 6507998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29393137 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 530
Study 29393137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study 27875567 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirming social influence condition
Number of subjects: 0
Study 27875567 — intervention group
Group type: COMPARATOR
Intervention: Disconfirming social influence condition
Number of subjects: 0
Study 27875567 — intervention group
Group type: COMPARATOR
Intervention: No social influence condition
Number of subjects: 0
Study 24841864 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Self-Change (GSC)
Number of subjects: 514
Study 24841864 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 514
Study 22486805 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sodium hypochlorite (NaOCl) with laser activation
Number of subjects: 148
Study 22486805 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sodium hypochlorite (NaOCl) without laser activation
Number of subjects: 148
Study 22486805 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile bi-distilled water with laser activation
Number of subjects: 148
Study 22486805 — intervention group
Group type: COMPARATOR
Intervention: Sterile bi-distilled water without laser activation
Number of subjects: 148
Study 20375690 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization and medical therapy
Number of subjects: 2146
Study 20375690 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone and deferred or no revascularization
Number of subjects: 2146
Study 20375690 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic control with insulin‐providing or insulin‐sensitizing drugs
Number of subjects: 2146
Study 20375690 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 2146
Study 18036421 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine nasal spray 0.2%
Number of subjects: 320
Study 18036421 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine nasal spray 0.4%
Number of subjects: 320
Study 18036421 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine nasal spray 0.6%
Number of subjects: 320
Study 18036421 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 320
Study 16094389 — intervention group
Group type: EXPERIMENTAL
Intervention: Assist/control with volume‐guarantee (AC+VG)
Number of subjects: 12
Study 16094389 — intervention group
Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation with volume guarantee (SIMV+VG)
Number of subjects: 12
Study 11880822 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercise (WEX) program, 12 weeks, 70 min per day, 3 days per week
Number of subjects: 30
Study 11880822 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercise (WEX) program
Number of subjects: 30
Study 11880822 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 10429496 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisc
Number of subjects: 60
Study 10429496 — intervention group
Group type: COMPARATOR
Intervention: Healon GV
Number of subjects: 60
Study 7481624 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry lactulose (Duphalac Dry)
Number of subjects: 62
Study 2210238 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipolar electrocoagulation
Number of subjects: 60
Study 2210238 — intervention group
Group type: COMPARATOR
Intervention: Injection therapy with absolute ethanol
Number of subjects: 60
Study 7192170 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling by a specialist nurse
Number of subjects: 152
Study 7192170 — intervention group
Group type: COMPARATOR
Intervention: Care normally given by the surgical unit (Control)
Number of subjects: 152
Study 31972599 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant capecitabine
Number of subjects: 0
Study 31972599 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and S‐1
Number of subjects: 0
Study 31972599 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine, cisplatin and S‐1 (GCS)
Number of subjects: 0
Study 31972599 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified FOLFOX (fluorouracil, leucovorin and oxaliplatin)
Number of subjects: 0
Study 31301658 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted transanal total mesorectal excision
Number of subjects: 6
Study 31301658 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic total mesorectal excision
Number of subjects: 6
Study 28102697 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-related implementation intentions (GI) delivered as text message reminders
Number of subjects: 8
Study 28102697 — intervention group
Group type: COMPARATOR
Intervention: Educational review regarding goals (GR)
Number of subjects: 8
Study 25867812 — intervention group
Group type: EXPERIMENTAL
Intervention: MTZ 30 mg/d for 42 days
Number of subjects: 22
Study 25867812 — intervention group
Group type: COMPARATOR
Intervention: Low-iodine diet (LID)
Number of subjects: 22
Study 23493674 — intervention group
Group type: EXPERIMENTAL
Intervention: SEPA (Salud, Educación, Prevención y Autocuidado) intervention
Number of subjects: 274
Study 21346717 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast diet
Number of subjects: 13
Study 21346717 — intervention group
Group type: COMPARATOR
Intervention: Non-breakfast diet
Number of subjects: 13
Study 19585653 — intervention group
Group type: EXPERIMENTAL
Intervention: Viramidine (VRD) 600 mg BID
Number of subjects: 972
Study 19585653 — intervention group
Group type: COMPARATOR
Intervention: Ribavirin (RBV) weight-based (1000 or 1200 mg/day)
Number of subjects: 972
Study 17391287 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 15539716 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast 20 mg (Z20)
Number of subjects: 641
Study 15539716 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast 160 mg (Z160)
Number of subjects: 641
Study 15539716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 641
Study 11815725 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose testosterone (LDT) 62.5 mg/m2
Number of subjects: 84
Study 11815725 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional dose testosterone (CDT) 125 mg/m2
Number of subjects: 84
Study 11815725 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple dose testosterone (MDT) 62.5 mg/m2
Number of subjects: 84
Study 11815725 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose testosterone (LDT)
Number of subjects: 84
Study 11815725 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional dose testosterone (CDT)
Number of subjects: 84
Study 9893912 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational propofol emulsion (Group A 2nd anaesthesia)
Number of subjects: 30
Study 9893912 — intervention group
Group type: COMPARATOR
Intervention: Control propofol emulsion (Group A 1st anaesthesia)
Number of subjects: 30
Study 9893912 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational propofol emulsion (Group B 1st anaesthesia)
Number of subjects: 30
Study 9893912 — intervention group
Group type: COMPARATOR
Intervention: Control propofol emulsion (Group B 2nd anaesthesia)
Number of subjects: 30
Study 9431481 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine or ergonovine maleate administration
Number of subjects: 45
Study 9431481 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous LAD spasms
Number of subjects: 45
Study 9431481 — intervention group
Group type: COMPARATOR
Intervention: Spasm of the diagonal branch
Number of subjects: 45
Study 1936695 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole pancreas with bladder diversion
Number of subjects: 171
Study 1936695 — intervention group
Group type: COMPARATOR
Intervention: Segmental pancreas transplantation
Number of subjects: 171
Study 6814472 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15-1788 (200 mg)
Number of subjects: 6
Study 6814472 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (40 mg)
Number of subjects: 6
Study 30798474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 0
Study 30798474 — intervention group
Group type: COMPARATOR
Intervention: Anodal tDCS
Number of subjects: 0
Study 30798474 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study 27512099 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based physiotherapy
Number of subjects: 30
Study 27512099 — intervention group
Group type: COMPARATOR
Intervention: Non-water-based physiotherapy
Number of subjects: 30
Study 27512099 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 30
Study 25947649 — intervention group
Group type: EXPERIMENTAL
Intervention: Running CPET
Number of subjects: 20
Study 25947649 — intervention group
Group type: EXPERIMENTAL
Intervention: All CPETs
Number of subjects: 20
Study 25163405 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinastine 0.05% ophthalmic solution
Number of subjects: 87
Study 25163405 — intervention group
Group type: COMPARATOR
Intervention: Placebo ophthalmic solution
Number of subjects: 87
Study 25163405 — intervention group
Group type: COMPARATOR
Intervention: Olopatadine 0.1% ophthalmic solution
Number of subjects: 87
Study 22530938 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) program, 8 weekly sessions of 2½ hours each.
Number of subjects: 37
Study 22530938 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) program
Number of subjects: 37
Study 19393415 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue adhesive
Number of subjects: 72
Study 19393415 — intervention group
Group type: COMPARATOR
Intervention: Surgical staples
Number of subjects: 72
Study 17255745 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 460
Study 17255745 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 460
Study 17255745 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 460
Study 15641876 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 16
Study 15641876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11944589 — intervention group
Group type: EXPERIMENTAL
Intervention: Etizolam administered after hematoma removal
Number of subjects: 39
Study 11944589 — intervention group
Group type: COMPARATOR
Intervention: Control group (not given etizolam)
Number of subjects: 39
Study 9483409 — intervention group
Group type: EXPERIMENTAL
Intervention: Eleutherococcus tincture for 20 days
Number of subjects: 0
Study 9483409 — intervention group
Group type: EXPERIMENTAL
Intervention: Elton and Leveton for 20 days
Number of subjects: 0
Study 8466023 — intervention group
Group type: EXPERIMENTAL
Intervention: A-3665 (0.25, 0.5, 1, 2, 4, 8, 16, 32, and 64 micrograms/kg)
Number of subjects: 45
Study 8466023 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (4, 8, or 16 micrograms/kg)
Number of subjects: 45
Study 8466023 — intervention group
Group type: EXPERIMENTAL
Intervention: A-3665 (16 micrograms/kg)
Number of subjects: 45
Study 8466023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 8466023 — intervention group
Group type: EXPERIMENTAL
Intervention: A-3665 (32 and 64 micrograms/kg)
Number of subjects: 45
Study 8466023 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (32 and 64 micrograms/kg)
Number of subjects: 45
Study 3768247 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g day‐1 for 7 days)
Number of subjects: 6
Study 3768247 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (300 mg day‐1 for 7 days)
Number of subjects: 6
Study 31360702 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive subjects
Number of subjects: 10553
Study 31360702 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP)
Number of subjects: 10553
Study 31360702 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP)
Number of subjects: 10553
Study 31360702 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension (categorical variable)
Number of subjects: 10553
Study 28675983 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluid (IVF) supplementation (50 mL/kg over 8 hours)
Number of subjects: 150
Study 28675983 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration solution (ORS) (50 mL over 8 hours)
Number of subjects: 150
Study 28675983 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 150
Study 26253748 — intervention group
Group type: EXPERIMENTAL
Intervention: MS Home Automated Telehealth (MS HAT) system
Number of subjects: 30
Study 26253748 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 30
Study 25457420 — intervention group
Group type: EXPERIMENTAL
Intervention: Video observation and PETTLEP mental training associated with physical practice
Number of subjects: 72
Study 25457420 — intervention group
Group type: COMPARATOR
Intervention: Physical practice alone
Number of subjects: 72
Study 22363616 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 kcal kg(‐1)⋅week(‐1) for 6 months at 50% VO2peak
Number of subjects: 390
Study 22363616 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 kcal kg(‐1)⋅week(‐1) for 6 months at 50% VO2peak
Number of subjects: 390
Study 22363616 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 kcal kg(‐1)⋅week(‐1) for 6 months at 50% VO2peak
Number of subjects: 390
Study 22363616 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercise)
Number of subjects: 390
Study 20048184 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU IFNalpha2a three times a week subcutaneously for 18 months (arm A)
Number of subjects: 850
Study 20048184 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU IFNalpha2a three times a week subcutaneously for 60 months (arm B)
Number of subjects: 850
Study 18843118 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-alum (20 microg, subcutaneous injections on study days 1 and 30)
Number of subjects: 70
Study 18843118 — intervention group
Group type: COMPARATOR
Intervention: Placebo (alum alone, subcutaneous injections on study days 1 and 30)
Number of subjects: 70
Study 18843118 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-alum
Number of subjects: 70
Study 18843118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 15879919 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone treatment
Number of subjects: 60
Study 15879919 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 60
Study 11918110 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer assisted learning
Number of subjects: 8
Study 11918110 — intervention group
Group type: COMPARATOR
Intervention: Book based learning
Number of subjects: 8
Study 10348471 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 12.5 mg clozapine
Number of subjects: 15
Study 10348471 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic clozapine treatment (39+/‐9 mg up to 50 mg) for 15.8+/‐7.7 months
Number of subjects: 15
Study 10348471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8598837 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor with intravenous oxytocin
Number of subjects: 5041